|
1
|
Ring KL, Pakish J and Jazaeri AA: Immune
checkpoint inhibitors in the treatment of gynecologic malignancies.
Cancer J. 22:101–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Quirk JT and Natarajan N: Ovarian cancer
incidence in the United States, 1992–1999. Gynecol Oncol.
97:519–523. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Auersperg N, Wong AS, Choi KC, Kang SK and
Leung PC: Ovarian surface epithelium: biology, endocrinology, and
pathology. Endocr Rev. 22:255–288. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matei D, Brown J and Frazier L: Updates in
the management of ovarian germ cell tumors. Am Soc Clin Oncol Educ
Book. 33:210–216. 2013. View Article : Google Scholar
|
|
6
|
Downs L and Boente MP: Germ cell
tumorsOvarian Cancer (Atlas of Clinical Oncology). Ozols RF: 1st.
BC Decker Inc.; Hamilton, Ontario: pp. 2252003
|
|
7
|
Deavers MT, Malpica A, Liu J, Broaddus R
and Silva EG: Ovarian sex cord-stromal tumors: an
immunohistochemical study including a comparison of calretinin and
inhibin. Mod Pathol. 16:584–590. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Colombo N, Peiretti M, Garbi A, Carinelli
S, Marini C and Sessa C: ESMO Guidelines Working Group:
Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 23(Suppl 7):
vii20–vii26. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
et al: SEER Cancer Statistics Review, 1975–2010. National Cancer
Institute; Bethesda, MD: 2013, http://seer.cancer.gov/csr/1975_2010/
|
|
10
|
Brown PO and Palmer C: The preclinical
natural history of serous ovarian cancer: defining the target for
early detection. PLoS Med. 6:e10001142009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Clarke-Pearson DL: Clinical practice.
Screening for ovarian cancer. N Engl J Med. 361:170–177. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sturgeon CM, Duffy MJ, Stenman UH, Lilja
H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ,
et al: National Academy of Clinical Biochemistry: National Academy
of Clinical Biochemistry laboratory medicine practice guidelines
for use of tumor markers in testicular, prostate, colorectal,
breast, and ovarian cancers. Clin Chem. 54:e11–e79. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schorge JO, Modesitt SC, Coleman RL, Cohn
DE, Kauff ND, Duska LR and Herzog TJ: SGO White Paper on ovarian
cancer: etiology, screening and surveillance. Gynecol Oncol.
119:7–17. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Buys SS, Partridge E, Black A, Johnson CC,
Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B,
et al: PLCO Project Team: Effect of screening on ovarian cancer
mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer
Screening Randomized Controlled Trial. JAMA. 305:2295–2303. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Coleman RL, Monk BJ, Sood AK and Herzog
TJ: Latest research and treatment of advanced-stage epithelial
ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vella N, Aiello M, Russo AE, Scalisi A,
Spandidos DA, Toffoli G, Sorio R, Libra M and Stivala F: ‘Genetic
profiling’ and ovarian cancer therapy (Review). Mol Med Rep.
4:771–777. 2011.PubMed/NCBI
|
|
17
|
Piccart MJ, Bertelsen K, James K, Cassidy
J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, et
al: Randomized intergroup trial of cisplatin-paclitaxel versus
cisplatin-cyclophosphamide in women with advanced epithelial
ovarian cancer: three-year results. J Natl Cancer Inst. 92:699–708.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dumontet C and Jordan MA:
Microtubule-binding agents: a dynamic field of cancer therapeutics.
Nat Rev Drug Discov. 9:790–803. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Katsumata N, Yasuda M, Takahashi F,
Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura
E, et al: Japanese Gynecologic Oncology Group: Dose-dense
paclitaxel once a week in combination with carboplatin every 3
weeks for advanced ovarian cancer: a phase 3, open-label,
randomised controlled trial. Lancet. 374:1331–1338. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Armstrong DK, Bundy B, Wenzel L, Huang HQ,
Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA:
Gynecologic Oncology Group: Intraperitoneal cisplatin and
paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gore M, du Bois A and Vergote I:
Intraperitoneal chemotherapy in ovarian cancer remains
experimental. J Clin Oncol. 24:4528–4530. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kigawa J: New strategy for overcoming
resistance to chemotherapy of ovarian cancer. Yonago Acta Med.
56:43–50. 2013.PubMed/NCBI
|
|
23
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herzog TJ and Pothuri B: Ovarian cancer: a
focus on management of recurrent disease. Nat Clin Pract Oncol.
3:604–611. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vaughan S, Coward JI, Bast RC Jr, Berchuck
A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R,
Etemadmoghadam D, et al: Rethinking ovarian cancer: Recommendations
for improving outcomes. Nat Rev Cancer. 11:719–725. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bookman MA, Brady MF, McGuire WP, Harper
PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De
Geest K, et al: Evaluation of new platinum-based treatment regimens
in advanced-stage ovarian cancer: a Phase III Trial of the
Gynecologic Cancer Intergroup. J Clin Oncol. 27:1419–1425. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stark D, Nankivell M, Pujade-Lauraine E,
Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J,
Lanceley A, et al: Standard chemotherapy with or without
bevacizumab in advanced ovarian cancer: quality-of-life outcomes
from the International Collaboration on Ovarian Neoplasms (ICON7)
phase 3 randomised trial. Lancet Oncol. 14:236–243. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Quintás-Cardama A, Kantarjian H and Cortes
J: Imatinib and beyond - exploring the full potential of targeted
therapy for CML. Nat Rev Clin Oncol. 6:535–543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sabatier R, Finetti P, Cervera N, Birnbaum
D and Bertucci F: Gene expression profiling and prediction of
clinical outcome in ovarian cancer. Crit Rev Oncol Hematol.
72:98–109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bajrami I, Frankum JR, Konde A, Miller RE,
Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, et al:
Genome-wide profiling of genetic synthetic lethality identifies
CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Cancer Res. 74:287–297. 2014. View Article : Google Scholar : PubMed/NCBI
|
